Antibodies are very efficient drugs, about 70 of them are already approved for medical use, 25 over 500 are in clinical development, and many more are in preclinical development. One 26 important step in the characterization and protection of a therapeutic antibody is the 27 determination of its cognate epitope. The gold standard is the 3D structure of the antibody-28 antigen complex by crystallography or NMR. However, it remains a tedious task and its 29 outcome is uncertain. We have developed MAbTope, a docking-based prediction method of 30 the epitope associated with straightforward experimental validation procedures. We show 31 that MAbTope predicts the correct epitope for each of 129 tested examples of antibody-32 antigen complexes of known structure. We further validated this method through the 33 successful determination of the epitopes recognized by two therapeutic antibodies targeting 34 tumor necrosis factor α (TNF-α): certolizumab and golimumab. 35 36
Introduction

37
The use of antibodies (Abs) as drugs against a large number of diseases has dramatically 38 increased in the last decade, and this tendency should still intensify in the near future (1) . 39 Because many antibodies are often developed against a same target, it has become essential 40 to determine the epitope of an antibody early in its development. Moreover, the 41 identification of the epitope is an important element in the understanding of Ab mechanism 42 of action (2). 43
Aside from 3D structures, most experimental methods available for epitope determination 44 are based either on (i) site-directed mutagenesis; (ii) peptide arrays (3-5) or (iii) mass 45 spectrometry (6). Most peptide-based methods use 15-30 amino acids overlapping peptides 46 of the target arrayed on solid support, which are then exposed to the antibody (4, 5). This 47 identification of interacting peptides can then be completed by alanine-scanning in order to 48 define the epitope more precisely (3). In the mass spectrometry-based approach, the 49 antibody-antigen complex is subjected either to hydrogen/deuterium exchange (HDX-MS) 50 (7), or to enzymatic digestion, which allows differentiating target peptides that are 51 "protected" by the presence of the antibody. These peptides can then be identified using 52 mass spectrometry (see (6) for a review). It should be noted that even when successful, 53 these different approaches are likely to provide non-identical definitions of the epitope. 54
Indeed, because of the crystallisation step that freezes the complex structure in one out of 55 many possible conformations, X-ray structure identifies only the most stable interactions. 56
Alanine scanning does not allow identifying all the interacting residues for different reasons: 57 the mutated amino acid might interact with the antibody through its main chain or the 58 mutation to alanine might not be drastic enough to give rise to a measurable difference in 59 affinity. Still, there is usually a large overlap between the epitopes identified by each method, 60 which corresponds to the core of the interface. 61
However, these approaches are expensive, time-consuming and, except crystallography, 62 remain error-prone. Indeed, the results obtained through HDX-MS are sometimes very 63 difficult to interpret, for example when there is a conformational change in the target 64 between the free and complexed forms (7) . Peptide arrays performance at identifying 65 epitopes are limited by different factors (8): immobilization methods, affinity of the peptides 66 and conformational constraints induced by the immobilization. For these reasons, many 67 efforts have been put in developing in silico methods capable of predicting antibody-antigen 68
interactions. This endeavour has taken two main directions: (i) B-cell epitope prediction, 69 which aims at predicting the regions of a protein that are the most amenable of being 70 targeted by an antibody; and (ii) partner-specific approaches, which aim at predicting the 71 epitope for a single antibody-target pair (see (9, 10) for reviews). Only the second type of 72 method leads to the prediction of the epitope for a given antibody, though B-cell epitope 73 prediction can be a useful first step in this process. Amongst the partner-specific approaches, 74 three main categories can be distinguished: predictors based on the intrinsic properties of 75 the partners, predictors based on co-evolution of the partners, and predictors based on 76 docking. However, few of these methods are dedicated to the special case of antibody-77 antigen interaction. 78
The aim of docking methods is originally the prediction of the conformation of the assembly 79 between two interacting proteins. From a correct prediction of this conformation, the 80 interaction regions can be straightforwardly defined. For this reason, docking methods have 81 been applied to the prediction of interaction interfaces, and in some cases the specific issue 82 of predicting the epitope and the paratope. Some methods provide accurate results, such as 83 Rosetta (11) and Z-dock (12), but in local docking only, meaning that they require a partial 84 knowledge of the epitope. The introduction of sDARS, a pairwise statistic potential specific of 85 antibody-antigen interactions, allows PIPER/Cluspro (which is the algorithm used for docking 86 within the Bioluminate suite) to achieve satisfactory results (13), placing at least one near-87 native solution in the top-10 predicted conformations. The particularity of this statistic 88 potential as compared to previously used ones is that it accounts for the asymmetry of the 89 antibody-antigen interaction. Another example of a web-server specific for antibody-antigen 90 docking is Frodock (14, 15). Frodock uses spherical harmonics for conformation generation 91 (as opposed to fast-Fourier transform for most other algorithms, including PIPER), and a 92 combination of energetic (van der Waals, electrostatics and desolvation) and knowledge-93 based potentials, optimized for the different categories of complexes (enzyme, antibodies 94 and others). However, the goal of these methods is predicting the conformation of the 95 assembly, meaning predicting the interaction region, but also the precise relative 96 orientations of the two partners, and not predicting the epitope. Even though they perform 97 better at this task than the other types of epitope prediction methods, they are not 98 optimized for it. 99
We have developed a new method for epitope determination, named MAbTope, which 100 integrates both a docking-based prediction method and experimental steps. Indeed, the 101 software part of the method automatically outputs peptides, without any human 102 intervention, that can be readily used for experimental validation. We also show how these 103 peptides can be used to design point mutations in the target, allowing a more precise 104 definition of the epitope. Thus, this method, although in part computational, is not just a 105 prediction method, but also includes the experimental validation of the epitope. 106
Material and methods
Overview of the method 109
The 3D structures of the antibody and of the target are used as input of the Hex software 110 (16) (Figure 1 ). Hex generates more than 10 8 docking poses and ranks them according to 111 energetic criteria (H-ranking). Each of the Hex top-500 docking poses is evaluated using 30 112 specific and 30 non-specific scoring functions. The non-specific scoring function is identical 113 to the one used in PRIOR (17), the specific scoring function has been re-optimised, using the 114 learning dataset described hereafter, and the same machine-learning procedure: genetic 115 algorithm and CMA-ES (18), and in both cases the area under the ROC-curve is used as 116 fitness function. A consensus score is then computed using the formula: is the ranking of pose i according to the specific function j. The rankings of 120 pose 0 (the best ranked according to Hex) are used for normalization. 121
For each pose, the algorithm also computes the A-score, C-score and P-score (see hereafter). 122
For each residue r of the target, we compute a value, Vr, which is the sum of the Hex ranks 123 of the poses in which r belongs to the interface. For a given pose, the A-score is the sum of 124 the Vr of the residues that belong to the epitope in this particular pose. For each pose, the C-125 score is the sum of the ranks of the other poses that have a RMSD value lower than 5 Å with 126 this particular pose. 127
The consensus, Hex-rank, A-score, C-score and P-score are used to generate 5 different 128 rankings. For each pose, the sum of its ranks in the different rankings is computed. These 129 numbers are used to generate the final ranking. The top 30 solutions are then used to 130 compute the interface frequency (IF) of each residue of the target, which is equal to the 131 number of poses within these 30 in which the residue belongs to the interface. This IF is used 132 to design the interface peptides (see hereafter). 133
P-score 134
A new post-processing function has been introduced: the P-score. For a given docking pose, 135
we count the number of CDR amino acids that are closer than 4Å to an atom of the target, 136 and normalize by the total number of CDR residues. The docking poses are then ranked by 137 decreasing values of this ratio. This rank is the P-score of the pose. 138
Specific learning dataset 139
The learning dataset is composed of 393 non-redundant antibody-target complexes 140 manually extracted from the PDB in January 2015. Only the complexes in which the target is 141 larger than 40 residues were considered. These complexes contain 392 distinct Abs and the 142 targets belong to 165 distinct Pfam families. The definition of non-redundancy we use is 143 weaker than what is usually used, since antibodies are very special proteins, and overall 144 sequence identity, even restricted to the variable domain, is not indicative of the antibody 145 specificity, and consequently on its ability to form a complex with its target. The criteria 146 retained for considering two Ab-Ag complexes as non-redundant were: (i) targets are not 147 related (they belong to different Pfam families); or (ii) targets are related but the epitopes 148 recognized by the antibodies have less than 20% overlap; or (iii) targets are related and 149 epitopes are overlapping but the CDRs of the considered antibody differ in 10 or more 150 positions. This third criterion is justified by the fact that most pairs of antibodies differing by 151 10 or more residues within the CDRs, even when they present a very high overall sequence 152 identity, do not share the same target. 153
Test dataset 154
To evaluate the performance of the method, a test dataset has been designed. It consists in 155 the 82 complexes of the learning dataset for which the 3D structures of the individual 156 partners are known. For the evaluation, the learning has been done in leave-one-out, 157 meaning that the epitope of a given antibody is predicted using a scoring function learnt on 158 a dataset not containing the 3D structure of the complex it forms with its target. Forty-seven 159 new complexes whose 3D structure has been determined after January 2015, and which 160 were non-redundant with those already present in the learning dataset have been added to 161 this test set. 162
We distinguished "small" targets (40 to 300 amino acid long) from "large" targets (more than 163 300 amino acid long). However, the results obtained for the two categories only slightly 164 differ. 165
Negative controls 166
In order to better evaluate the method performance, we have included negative controls. To 167 this aim, we have compared, for each target of the test set, the epitope predicted by docking 168 each of the non-cognate Abs of the test set to the actual epitope. 169
Epitope definition 170
In this work, an amino acid of a protein targeted by an antibody will be considered as 171 belonging to the epitope if at least one of its atoms is at less than 4 Å of an atom belonging 172 to an amino acid of the antibody. These distances are computed on the crystallographic 173 structure of the complex. 174
Definition of epitope peptides 175
Each amino acid of the target is attributed a value, which is the number of poses within the 176 30 top-ranked ones in which this amino acid belongs to the predicted epitope. Different sizes 177 of pose sets have been tested, and 30 is a satisfactory compromise (data not shown). Each 178 15 amino acid peptide of the sequence is then given a score equal to the sum of these values 179 for each amino acid in the peptide. The peptides are then ranked along this score. Peptides 180 overlapping by at least 8 amino acids with a better-ranked peptide are ignored. For 181 benchmarking, the relevance of a given peptide is evaluated by the number of residues that 182 belong to the crystallographic epitope. This definition of epitope peptide was also used for 183 the testing of Cluspro and FRODOCK. In EpiPred predictions, amino acids present in the first 184 predicted epitope were given a score of 3, a score of 2 for the amino acids of the second 185 epitope and a score of 1 for the amino acids of the third epitope. In PPiPP predictions, the 186 scores given in the program output were considered. Epitope peptides were then built as 187 explained above. 188
The choice of 15 mers is a compromise between two empirical observations we have made 189 along the development of this method. (i) Shorter peptides tend to give a poor signal. Our 190 hypotheses are that they are too flexible (short peptides present less long-range interactions 191 and are thus more flexible), which decreases their binding to the antibody. Moreover, the 192 secondary structure is important for binding, and very short peptides have no chance to 193 adopt hairpin or strand conformations. (ii) Longer peptides tend to span over more than one 194 loop, and interpretation of experimental results is then more difficult. A second aspect is 195 that longer peptides have a higher tendency to precipitate. 196
Evaluation criteria 197
MAbTope first output is a ranked list of docking poses. To evaluate the distance between 198 these poses and the native solution, CAPRI criteria were used (19): 199 Introducing this new category is very useful for evaluating docking performance in the 212 perspective of epitope determination. Indeed, the docking poses falling in this category, 213 even though their geometry is too distant from the crystal structure to be considered as 214 acceptable by the Capri criteria, still define an interaction area on the target that overlaps 215 with the actual epitope, and thus give valuable information on the epitope. 216
To evaluate the docking performances of our algorithms, for each complex in the test set we 217 calculate the rank of the first near-native pose with the CAPRI criteria and with our own 218 criteria (CAPRI + indicative). 219
The second output of MAbTope is a list of peptides, ranked on the predicted probability they 220 match with the epitope. To evaluate the epitope prediction accuracy, we calculate the 221 number of residues in each peptide that belong to the actual epitope (and do not belong to 222 better ranked peptides), normalized by the total number of residues in the epitope. for the antibody and the fact that the dissociation is almost immediate, we restrained the 237 dissociation analysis to the 20 first seconds. Global analyses of the datasets assuming that 238 binding was reversible (full dissociation) were carried out using nonlinear least-squares 239 fitting, allowing a single set of binding parameters to be obtained simultaneously for all 240 concentrations used in each experiment. 241
HTRF-based competition assay 242
The competition between Golimumab and either the Certolizumab or the peptides for the 243 TNFα was assessed in vitro using an HTRF ® -based assay in 384-well plate. The Golimumab 244 and the Certolizumab were kindly provided by Denis Mulleman (CHRU Bretonneau, Tours, 245 used to measure the interaction between the different peptides and the antibody. Graphs 286 are generated using GraphPad Software (GraphPad Prism 5 Software, San Diego, CA, USA). 287
In vitro FRET binding measurement 288
The interaction between the different biotinylated peptides (GeneCust, Dudelange, 289 Luxembourg) and Certolizumab, or Golimumab, or Eculizumab used as a negative control, 290 was assessed by HTRF ® . All experiments were performed in PPI-Terbium or -Europium 291 detection buffers (CisBio Bioassays, Condolet, France). For this, 5 µL of biotinylated peptides 292 (4 mM) were first incubated with 5 µL of either of the mAbs (1.6 µg/mL) for 1 hr at room 293 temperature. Then, 5 µL of streptavidin and 5 µL of anti-Fab (for Certolizumab) or anti-Fc 294 
Results
Principle and Benchmarking 351
MAbTope involves three successive steps. The first step is the docking of the antibody on its 352 target, which results in the generation of docking poses (possible conformations of the 353 antibody-antigen complex), through a method related to PRIOR, a general protein-protein 354 docking method we had previously developed (17, 21, 22) . The second step is the ranking of 355 these docking poses in order to extract 30 poses that tile the epitope, and the design of four 356 so-called interacting peptides, that is, peptides predicted to be part of the epitope. The third 357 step is the experimental validation based on the interacting peptides. Different methods can 358 be used: measurement of the binding of each of these four peptides with the antibody, 359 competition for antibody binding between the peptides and the target, or measurement of 360 the binding of target mutated on residues belonging to these peptides. 361
The design of the interacting peptides from the docking poses is crucial for the success of the 362 method. At this step, all the possible 15 amino acid-long peptides of the target are ranked 363 according to the frequency at which their amino acids are found within the epitope in the 30 364 top-ranked docking poses. MAbTope predicts a correct peptide, that is, a peptide that 365 contains residues belonging to the crystallographic interface, within the 4 best-ranked ones 366 for all of the 129 complexes tested. On average the 4 best-ranked peptides contain more 367 than 80% of the epitope residues, and the minimum is 30%, meaning that the epitope is at 368 least partly found for all complexes in the test set ( Figure 1A , Table S1 ). As a control, each 369 antibody of the test set was docked to all the targets of the other antibodies. In this test, on 370 average only 36 % of the residues belonging to the epitope of the specific antibody are 371 found within the 4 best-ranked peptides. 372
MAbTope performs much better than Cluspro or FRODOCK at predicting the epitopes, as 373 they identify, within the 4 best-ranked peptides, 36 % and 35 % of the epitope residues 374 respectively. One reason is that, in MAbTope, the 30 top docking poses are centred on the 375 correct epitope, and not distributed on the whole surface of the target. This is illustrated in 376 Figure S3 ). In addition, peptides 385 1 and 2 contain 7 and 6 amino acids belonging to the epitope, respectively. It should be 386 noted that peptides 3 and 4 also contain 8 and 6 residues, respectively, and can also be 387 considered as good predictions. Finally, the 6 best-ranking peptides contain all the amino 388 acids belonging to the epitope. 389
We also compared the performance of MAbTope to that of two non-docking-based epitope 390 prediction methods: PPiPP (24) and EpiPred (25). The results show that MAbTope clearly 391 outperforms these two methods, confirming that a detailed consideration of shape and 392 electrostatic complementarity, which results from the docking procedure, is necessary for 393 high quality predictions ( Figure 1B , Table S1 ). 394
The last step of the method consists in the experimental validation. Our first approach 395 consists in measuring the binding of the antibody to the peptides. For each designed peptide, 396 three peptides are synthesized, all of the same length but sliding three amino acids along the 397 sequence. The first one starts and ends 3 amino acids upstream of the designed epitope 398 peptide, the second one corresponds to the designed one, and the third one starts and ends 399 3 amino acids downstream. This choice was made to overcome the issue of some peptides 400 being insoluble. A second approach is to measure the competition between these peptides 401 and the target for the binding of the antibody. Finally, as the residues present within these 402 peptides are those predicted to belong to the epitope, they can be used to predict point 403 mutations of the target reducing the binding of the antibody. 404
It should be highlighted that MAbTope is able to find the epitope of each antibody, and not 405 only the most antigenic sites on the target protein as defined by B-cell epitope prediction 406 methods. This is well illustrated by the example of gp120, to which 25 antibodies of the 407 benchmark bind. Whereas some regions of gp120 are targeted by a large number of 408 antibodies, including some that do not belong to the benchmark since the structure of the 409 isolated antibody is not known, other regions are also targeted. Accordingly, the interaction 410 peptides designed through MAbTope are spread on the whole target sequence (Figure 2) . 411
MAbTope correctly builds at least one correct peptide for each of these 25 antibodies, and 412 two peptides for 19. 413
Validation on golimumab and certolizumab 414
To validate the method, we next predicted the epitopes of two therapeutic antibodies 415 targeting Tumor Necrosis Factor α (TNF-α): golimumab and certolizumab. These two 416 antibodies are already widely used in clinic, but their respective epitope is still unknown. We 417 built homology models of the two antibodies and used MAbTope to predict the epitopes 418 they bind. On the basis of the predicted epitope-antibody interface, four different sets of 419 peptides have been selected and synthesized (G1 to G4 for golimumab and C1 to C4 for 420 certolizumab, Figure 4 ). The P1 family overlaps with G3 and C4, and corresponds to the 421 region containing the highest overlap between both predictions. The P4 family overlaps with 422 C2 and G4. The P3 family overlaps with G1 and C1. Finally, the P2 family does not overlap 423 with a 4-top predicted peptide, but lies in a region well exposed and predicted by MAbTope 424 to belong to certolizumab epitope but not golimumab one. Peptides G2 and C3 were ignored 425 since they are partly buried and have consequently low chances to interact efficiently with 426 the antibody. 427
After the initial submission of this paper, the structure of the complex between certolizumab 428 and TNF-α has been published (26). Comparison with our prediction shows that out of the 20 429 residues constituting the epitope, 17 belong to peptides C1 to C4 ( Figure 3A ). This shows 430 that certolizumab epitope can be considered as conformational since it involves residues 431 belonging to five different peptides. Nevertheless, we are still able to show the specific 432 binding of some of these peptides to the antibody through HTRF and interferometry ( Figure  433 S4). 434
To validate the epitope of golimumab, we first have shown that it competes with 435 certolizumab for the binding to TNF-α, using HTRF ( Figure 4A and S5). We thus performed 436 further experimental validations on golimumab solely. We have also shown, using both HTRF 437 and peptide array (RPPA), that golimumab specifically binds the P3-1, P3-2 and P3-3 peptides 438 ( Figures 4B and 4C ). Finally, we have shown, using HTRF, that peptides P1-1, P1-2, P1-3, P3-1 439 and P3-3 decrease the binding of golimumab to TNF-α in a dose-dependent manner. Note 440 that we observe a strong competition with the P1 series peptides in this last experiment, 441 whereas we could not observe the binding of these peptides in the direct binding 442 experiments. One hypothesis is that the biotin, which is attached at the N-ter of the peptide 443 in the direct binding experiments, could prevent the binding to the antibody. The specificity 444 of the binding of the P1 series peptides is confirmed by the flow cytometry experiments 445 presented hereafter. 446
To further validate, we mutated in TNF-α the residues belonging to peptides of series 1, 3 447 and 4 to alanines, and observed the binding of golimumab using flow-cytometry ( Figure 5A  448 and S6). We observed that each TNF-a construct expressed well in cells by detecting flag 449 epitope that was added to all constructs. Interestingly, we found that the binding of 450 golimumab its target was almost abolished when the TNF-α was mutated at positions 451 indicated within P1 and P3 series, and reduced by 50% for mutations within the P4 series 452 peptides. Finally, for peptides P3-1 and P3-3, which gave the best signals in HTRF, we 453 mutated individually the residues belonging to these peptides and whose side-chains are 454 exposed, and measured the binding to golimumab using HTRF ( Figure 5C and 5D ). These 455 results show that, as predicted, residues Y172, T174 and K175 are essential for golimumab 456 binding to TNF-α. 457
Discussion
458
The results obtained on the 129 antibody-target complexes of the benchmark show that the 459 in silico prediction is robust, since within the benchmark, the predicted peptides contain on 460 average 80 % of the epitopes residues. This number is not much affected by the type of 461 epitope: 79 % for conformational epitopes (105 out of 129), 89% for linear epitopes (14 out 462 of 129). Neither is it much affected by the size of target: 88 % for targets up to 300 residues 463 long, 70 % for larger targets. The main limitation of the in silico step is that the 3D structure 464 of the target is needed. We have already tested the approach using homology models of the 465 target when the 3D structure is not available. Although good results could be obtained is the 466 few tested cases, this requires further investigations. 467
Based on the designed peptides, we present three different experimental validations of the 468 predicted epitope. Our first approach consists in measuring the direct binding of the 469 designed peptides, either through HTRF, peptide array or through interferometry. Good 470 results could be obtained for the golimumab peptides of series 3. However, no signal is 471 observed for series 1 peptides, although we later demonstrate that these peptides belong to 472 the epitope. The second approach consists in making a competition between the peptides 473 and the target for the binding of the antibody. Using this method we were able to validate 474 the peptides of series 1, and confirm the peptides of series 3. Nevertheless, both approaches 475 are limited by the fact that some peptides tend to be "sticky". Another limit to these 476 approaches is the solubility of peptides, which is not always sufficient. 477 Importantly, the interaction peptides can also be used to design point-mutations in the 478 target potentially decreasing the affinity of the antibody. In the TNF-α we mutated to 479 alanines the residues belonging to peptide series 1, 3 and 4 whose side-chains point towards 480 the solvent. We show using flow cytometry that these mutations indeed abolish (series 1 481 and 3) or decrease (series 4) the binding of the antibody. However, this approach also has its 482 limitations: the difficulty of expressing some target or their mutated forms, especially if they 483 are toxic for the cells. The endogenous expression of the native target could also raise some 484 issues. 485
Despite the known limitations of each experimental approach proposed, it is reasonable to 486 assume that their combined use will convey more robustness to the overall validation 487 process. 488
Further demonstration of MAbTope ability to determine the epitope is given through the 489 examples of certolizumab and golimumab. For these two antibodies, although their 3D 490 structure was not known at the beginning of this study, we were able to predict and 491 experimentally validate the epitopes. A good example is given by peptide 1.3, which contains 492 only one residue belonging to the epitope, but for which we were able to measure the 493 specific binding with certolizumab ( Figure S4 ). Using mutated peptides we were also able to 494 refine these results, and show the importance of individual residues in the epitope. 495
Two other therapeutic antibodies are used in clinic for their ability to bind TNF-α: infliximab 496 and adalimumab, and the 3D structures of the corresponding complexes with the target are 497 known [4G3Y for infliximab (27) and 3WD5 for adalimumab (28)]. A recent meta-analysis has 498 compared the efficacy of different TNF-α-blocking agents, including the four antibodies cited 499 above. It concludes that infliximab and golimumab are less efficient in the treatment of 500 rheumatoid arthritis than adalimumab and certolizumab (29). By contrast, a meta-analysis 501 performed in ulcerative colitis indicated that infliximab is better than adalimumab and 502 probably golimumab (30). Their affinities for TNF-α (4.5 x 10 -10 M for infliximab (28), 7.05 x 503 10 -11 M for adalimumab (28), 1.8 x 10 -11 M for golimumab (31) and 1.32 x 10 -10 M for 504 certolizumab (US patent US20050042219 A1) do not explain these differences. Hu et al. (28) 505 hypothesized that the difference of efficacy between infliximab and adalimumab could be 506 partly due to the fact that adalimumab binds in the groove between two monomers, and has 507 consequently a higher overlap with the TNF-α receptor binding interface and a better 508 neutralizing activity, than infliximab, which binds to a monomer. By contrast, the ability to 509 target inflammatory cells expressing membrane TNF-a, which could be monomeric, and to 510 induce apoptotic signals seems important determinants of therapeutic activity of anti-TNF-α 511 agents in inflammatory bowel diseases (32). These reasons could also account for the 512 difference of efficacy between certolizumab and golimumab, as certolizumab binds in the 513 groove (like adalimumab), whereas golimumab binds to the monomer ( Figure S7 ), knowing 514 that certolizumab differs from the three others by its monovalency and the absence of an Fc 515 region. However, the fact that the structure of the four anti-TNF-a therapeutic antibodies is 516 now known will help at understanding the subtle differences in their clinical activities. 517 518
Conclusion 519
In conclusion, MAbTope initial prediction of the epitope is very robust. On a benchmark of 520 129 antibody-antigen complexes, MAbTope correctly defines the epitope in each case. In 521 addition, MAbTope allows defining four 15 amino acid peptides, among which at least one 522 belongs to the epitope, which in turn allows experimental validation. These peptides also 523 allow the design of point mutations that can be used to validate and refine the predicted 524 epitope. Although the information obtained through MAbTope does not allow defining the 525 precise interactions taking place between the antibody and the target, it allows defining with 526 good precision the region of the target involved in the interaction. This information is 527 sufficient for understanding the mechanism of action of the antibody, a crucial step in the 528 development of therapeutics, but also diagnostic or biotechnological tools. Taken together, 529
MAbTope is not just a prediction method, but constitutes an integrated workflow allowing 530 identification of the epitope. With the example of two therapeutic antibodies, certolizumab 531 and golimumab, we show that it can be successfully applied to antibodies whose 3D 532 structure is unknown. 533 534 Bibliography The designed peptides are all mapped on the sequence of 4ZMJ (chains B and G of GP120), 654 although some of the antibodies target gp120 proteins of different clades. However, the 655 epitopes recognized by the different antibodies have a homologous region in 4ZMJ. Each 656
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